Should You Follow Warren Buffett And Dump GlaxoSmithKline plc?

The world’s greatest investor has dumped his holding in GlaxoSmithKline plc (LON:GSK), should you follow suit?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gsk

It was recently revealed that Warren Buffett, widely considered to be one of the world’s best investors, had sold off his entire shareholding in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

While it is true that Glaxo was never a huge holding for Buffett, amounting to less than 0.1% of the investment managers’ portfolio, we should try and establish why Buffett made this move and whether or not you should be concerned.

Glaxo has been underperforming

One the reasons behind Buffett’s sale, could be do with Glaxo’s poor performance during the past few years. In particular, due to the loss of exclusive manufacturing rights for a number of key treatments, Glaxo’s revenue, operating income and earnings per share have all ticked lower during the past five years. Unfortunately, over the same period, many of Glaxo’s international peers have reported rising sales and earnings.

In addition, Glaxo’s debt has been rising faster than that of its peers during the same period. For example, at present Glaxo’s net debt to equity ratio currently stands at around 200%. Meanwhile, the average net debt to equity ratio of the company’s international peers, including Pfizer, Sanofi and Johnson & Johnson is less than 50%. 

But above all…

However, Buffett’s biggest concern could be to do with Glaxo’s management team. You see, Buffett only likes to invest in companies with strong management teams and more importantly, management teams that can be trusted. Sadly, recent mistakes, particularly within China, have proven that Glaxo’s management team cannot be trusted.

Specifically, Glaxo’s management team broke Chinese bribery the laws to encourage sales of their treatments. This has dented the company’s sales and reputation within what is becoming the most important market in the world for many companies. To be precise, Glaxo’s sales within China collapsed 60% during one quarter alone last year. In comparison, peers such as London-listed AstraZeneca have seen sales in China jump. Glaxo’s rising debt and sliding sales are further indications that management could have made some mistakes.

Actually, Buffett has previously made it clear that he will dispose of his holding in companies with managements that have failed shareholders. Indeed, the world most prolific investor sold his holding of international drugs giant Johnson & Johnson several years ago citing that, “there had just been too many mistakes”.

Should you follow Buffett’s move?

But the key question is, should you follow Buffett and dump your holding in Glaxo? Well, investors need to trust company management teams to run business well on their behalf and Glaxo’s management has proven that it can’t be trusted.

That being said, Glaxo is well positioned for growth over the next few years. The company has a with a strong treatment pipeline and sales growth within China should pick up in the long-term. So, as of yet, despite mistakes within China, I wouldn’t follow Buffett’s move to offload Glaxo just yet. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in GlaxoSmithKline. 

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »